{"task_id": "e0f71532c2c61471", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 180/464)", "text": "on\nand sudden death\n168\nAcute Myelogenous Leukemia\n\n--- Page 190 ---\nAcute Lymphoblastic Leukemia\nNEJM 2006 354:2\nPATHOPHYSIOLOGY\nHISTOLOGIC TYPE\n\u0002 FAB L1\nsmall, uniform lymphoblasts with indis\ntinct nucleoli\n\u0002 FAB L2\nlarger, pleomorphic lymphoblasts with\nlow nucleus to cytoplasm ratio and clear nucleoli\n\u0002 FAB L3\nlarge, pleomorphic lymphoblasts with\nbasophilic cytoplasm, large nucleoli, vacuoles\nWHO CLASSIFICATION\n\u0002\nPRECURSOR B CELL (L1, L2)\n\u0002\nPRO-B ALL\nresembles an early stage of B cell\n\u0002\nPRE-B-CELL ALL\nintracytoplasmic immunoglobulin\n\u0002 B-CELL ALL\nexpress surface immunoglobulin\n\u0002\nPRECURSOR T CELL (L1, L2)\n\u0002\nBURKITT-LIKE ALL (L3)\nRISK FACTORS FOR ALL\nold age, previous che\nmotherapy or radiation, Down\u2019s syndrome\nCLINICAL FEATURES\nPANCYTOPENIA\nweakness, fatigue, infections, gin\ngival\nbleed,\necchymosis,\npetechiae,\nepistaxis,\nmenorrhagia\nORGAN INVOLVEMENT\nlymphadenopathy, hepa\ntomegaly, splenomegaly, bone pain, cranial nerve\npalsies, headaches\nNOTE: precursor B lymphoblastic lymphoma is asso\nciated with lymphadenopathy/extranodal involve\nment and < 25% blasts, while precursor T LBL is\nassociated mediastinal mass and < 25% blasts\nDISTINGUISHING FEATURES BETWEEN AML AND\nALL\nAML\nPrecursor ALL\nBlasts\nLarger\nSmall\nAuer rods\n+\nTdT\n+\nMPO\n+\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, smear, lytes, urea, Cr, Ca, PO4, Mg,\nuric acid, albumin, urinalysis, LDH, INR, PTT, fibri\nnogen, flow cytometry of peripheral blood\n(immunophenotyping)\n\u0002\nBONE MARROW BIOPSY\n>25% blast, flow cyto\nmetry for immunophenotyping, cytogenetic\nanalysis (detection of BCR ABL fusion and chro\nmosomal abnormalities with pulsed field gel\nelectrophoresis and/or RT PCR)\n\u0002\nLUMBAR PUNCTURE\nCSF for cytology\n\u0002\nTISSUE BIOPSY\nlymph node, skin, mediastinal\nmass\nINVESTIGATIONS (CONT\u2019D)\nSPECIAL\n\u0002\nIMAGING\nMUGA scan\n\u0002 HLA\nTESTING\nto assist in obtaining HLA\nmatched platelets if needed during treatment\nand to find HLA matched allogeneic bone\nmarrow\nPROGNOSTIC ISSUES\nPROGNOSTIC FACTORS\nwhile childhood ALL is\ncurable in 85% of cases, adult ALL has a worse prog\nnosis, with a 5 year survival of 35%. Factors asso\nciated with poorer survival include the following:\n\u0002\nCLINICAL\nlack of response to induction therapy\n(most important), old age, leukocyte count, CNS\ninvolvement\n\u0002\nCYTOGENETICS\nBCR ABL fusion or t(9;22) (also\nknown as the Philadelphia\nchromosome, in\n20 50% of adults), MLL AF4 fusion or t(4;11) (in\n5 6% of adults), t(8;14), t(1;19), hypodiploidy\n( < 45 chromosomes/cell), del(7), trisomy\n\u0002\nFAVORABLE PROGNOSIS\nhyperdiploidy, del(9), TEL\nAML1 fusion or t(12;21) (in 10% of adults)\nRISK CATEGORIES\n\u0002\nHIGH RISK\nany of age >60, t(9;22) or bcr abl,\nt(4;11), t(1;19); WBC >30\u0003103/mL in B ALL or\n>100\u0003103/mL in T ALL or pro B ALL\n\u0002\nSTANDARD RISK\nnone of high risk features\nRISK\nFACTORS\nFOR\nCNS\nRELAPSE\nhigh risk\ngenetic features, T ALL, large tumor burden, CSF\npositivity\nMANAGEMENT\nREMISSION INDUCTION THERAPY\ncombination\nchemotherapy\nwith\nprednisone,\nvincristine,\nan\nanthracycline \u0004 asparaginase, and cyclophospha\nmide. Complete response 80 90%. Management of\nspecific subgroups include\n\u0002 PH+ ALL\nadd imatinib\n\u0002 B-CELL ALL\ntreat as aggressive non Hodgkin\u2019s\nlymphoma\n\u0002 T-CELL ALL\ntreat with cyclophosphamide con\ntaining regimens\nCNS PROPHYLAXIS\nto start after remission with\nintrathecal methotrexate with high dose systemic\nmethotrexate. Consider cranial radiation for patients\nat high risk of CNS relapse\nINTENSIFICATION/CONSOLIDATION THERAPY\n\u0002\nSTANDARD RISK\nconsolidation chemotherapy with\nvarious combinations of cyclophosphamide, 6\nmercaptopurine,\ncytarabine,\nvincristine,\nand\ndoxorubicin\nAcute Lymphoblastic Leukemia\n169", "text_length": 3593, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 180/464)", "type": "chunk", "chunk_index": 179, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.493267", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.494005", "status": "complete", "chunks_added": 2}